Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.42 |
| ▸ | CTSK | P43235 | 11/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721657 | 1.00 | CTSS (0.42) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL21724438 | 1.00 | CTSS (0.42) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL30910798 | 0.90 | REN (0.41) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL214303 | 0.88 | ITGB3 (0.48) | CTSSCTSKCTSLCTSBITGB3 | |
| SCHEMBL1133305 | 0.88 | ITGB3 (0.48) | CTSSCTSKCTSLCTSBITGB3 | |
| SCHEMBL214302 | 0.88 | ITGB3 (0.48) | CTSSCTSKCTSLCTSBITGB3 | |
| SCHEMBL15663691 | 0.88 | CYP1A2 (0.41) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL30065429 | 0.88 | CTSS (0.42) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL30629214 | 0.88 | CTSS (0.42) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL30364981 | 0.86 | KMT2A (0.44) | CTSSCTSKCTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | CTSS 653/4885CTSK 963/4885CTSL 390/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | CTSS 653/4885CTSK 963/4885CTSL 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.